UK's MHRA approves Cidara's REZZAYO for adult invasive candidiasis treatment, following positive Phase 3 trial results.

Cidara Therapeutics announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has approved REZZAYO (rezafungin acetate), their treatment for invasive candidiasis in adults. This follows positive results from the ReSTORE Phase 3 clinical trial. Cidara has partnered with Mundipharma, which has commercial rights to rezafungin outside the U.S. and Japan. The company is entitled to receive a $2.8 million payment for the MHRA approval.

January 29, 2024
6 Articles